<DOC>
	<DOCNO>NCT00020722</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation plus biological therapy may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : This phase II trial study well chemotherapy follow peripheral stem cell transplantation plus biological therapy work treat woman stage IV breast cancer .</brief_summary>
	<brief_title>Chemotherapy Followed Peripheral Stem Cell Transplantation Plus Biological Therapy Treating Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether use autologous peripheral blood stem cell transplantation follow immunotherapy activate T cell woman stage IV breast cancer improve progression-free survival ( PFS ) compare report mean PFS patient treat second-line chemotherapy match inclusion criterion publish trial . - Determine regimen improve clinical response overall survival . - Perform sequential immune monitoring study , include phenotyping , cytotoxic assay , EliSpots IFNγ , select T-cell repertoire ( Vβ analysis ) , HER2/new tetramer analysis , serum tumor marker . - Test correlation immune function test clinical endpoint . OUTLINE : Patients stratify accord tumor classification ( chemosensitive v chemoresistant ) . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily 4 day follow peripheral blood mononuclear cell ( PBMC ) collection PBSCT generation activate T cell ( ATC ) . The PBMC treat ex vivo monoclonal antibody OKT3 form ATC . The ATC expand 12-14 day interleukin-2 ( IL-2 ) . Patients receive high-dose chemotherapy . Patients chemosensitive disease receive cyclophosphamide IV 1 hour , thiotepa IV 1 hour , carboplatin IV 1 hour day -4 , -3 , -2 . Patients chemoresistant disease receive ifosfamide IV 1 hour , etoposide IV twice daily , carboplatin IV 1 hour day -8 -3 . Patients undergo autologous PBSC transplantation day 0 day 0 day 1 . Patients receive ATC IV 15-20 minute three time per week start approximately day +1 three week weekly least 6 dos . After completion study therapy , patient follow periodically 2 year PBSC .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Women histologically document metastatic carcinoma breast Bilateral disease allow Concurrent intraductal lobular carcinoma situ allow Measurable evaluable recurrent metastatic disease ( stage IV ) document radiograph , CT scan , nuclear medicine scan , physical exam Biopsy recurrent site ( ) recommend require Nonmeasurable disease allow tumor metastatic disease previously remove successfully treat 0 3+ HER2 amplification , determine FISH No clinical evidence active brain metastasis Patients treat brain metastasis ( i.e. , receive definitive radiation , chemotherapy , and/or underwent surgery ) stable eligible Hormone receptor status : Estrogen progesterone receptor positive negative PATIENT CHARACTERISTICS : Menopausal status specify Karnofsky performance status 70100 % OR ECOG performance status 02 Life expectancy least 3 month Granulocyte count least 1,500/mm^3 Platelet count least 50,000/mm^3 Hemoglobin great 8 g/dL Bilirubin le 1.5 time normal AST , ALT , alkaline phosphatase &lt; 5 time upper normal Creatinine le 1.8 mg/dL Creatinine clearance least 60 mL/min BUN less 1.5 time normal No myocardial infarction ( MI ) within past year No history MI ( &gt; 1 year ago ) current coronary symptom require medication No current history angina/coronary symptom require medication No clinical evidence congestive heart failure require medical management No significant congestive heart failure No uncontrolled significant cardiovascular disease Ejection fraction least 45 % rest MUGA Systolic BP &lt; 130 mm Hg diastolic BP &lt; 80 mm Hg BP must control meet standard antihypertensive medication least 7 day prior first infusion PFTFEV_1 least 50 % predict DLCO2 least 50 % predict FVC least 50 % predict No malignancy within past 3 year No serious medical psychiatric illness would preclude study participation HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior chemotherapy regimen allow , include prior treatment protocol WSU2006130 Prior vaccine therapy protocol WSU2006130 allow More 4 week leukapheresis since prior hormonal therapy No radiation axial skeleton within 4 week leukapheresis No concurrent hormonal therapy breast cancer Hormones administer nondiseaserelated condition ( e.g . insulin diabetes ) allow Concurrent steroid adrenal failure , septic shock , pulmonary toxicity allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>